Shanxi C&Y Pharmaceutical Group Co Ltd Net Asset Quality Index
Shanxi C&Y Pharmaceutical Group Co Ltd net asset quality index. Shanxi C&Y Pharmaceutical Group Co Ltd (300254) has a Net Asset Quality Index of 34.5% as of June 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥1.53 Billion minus total liabilities of CN¥1.00 Billion yields net assets of CN¥527.01 Million. A higher index indicates a stronger, lower-leverage balance sheet. See 300254 total equity for net asset value and shareholders' equity analysis.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Shanxi C&Y Pharmaceutical Group Co Ltd (2008–2025)
Net asset quality index of Shanxi C&Y Pharmaceutical Group Co Ltd from 2008 to 2025. This chart shows how Shanxi C&Y Pharmaceutical Group Co Ltd's Net Asset Quality Index has evolved across 18 annual periods from 2008 to 2025. As of June 2026, the index stands at 34.5%, representing net assets of CN¥527.01 Million against total assets of CN¥1.53 Billion CNY. Check 300254 PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Shanxi C&Y Pharmaceutical Group Co Ltd Net Asset Quality Index by Year (2008–2025)
Shanxi C&Y Pharmaceutical Group Co Ltd net asset quality index by year from 2008 to 2025. The table below presents the year-by-year Net Asset Quality Index for Shanxi C&Y Pharmaceutical Group Co Ltd from 2008 to 2025, covering 18 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see Shanxi C&Y Pharmaceutical Group Co Ltd market cap and net worth.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 36.2% | CN¥594.33 Million | CN¥1.64 Billion | CN¥1.05 Billion | ▼ -2.5 pp |
| 2024 | 38.6% | CN¥598.18 Million | CN¥1.55 Billion | CN¥949.55 Million | ▼ -15.7 pp |
| 2023 | 54.3% | CN¥778.43 Million | CN¥1.43 Billion | CN¥654.64 Million | ▲ +8.3 pp |
| 2022 | 46.1% | CN¥729.68 Million | CN¥1.58 Billion | CN¥854.64 Million | ▼ -2.7 pp |
| 2021 | 48.8% | CN¥744.58 Million | CN¥1.53 Billion | CN¥782.23 Million | ▲ +0.3 pp |
| 2020 | 48.5% | CN¥872.61 Million | CN¥1.80 Billion | CN¥927.91 Million | ▼ -3.3 pp |
| 2019 | 51.8% | CN¥932.60 Million | CN¥1.80 Billion | CN¥869.43 Million | ▼ -10.5 pp |
| 2018 | 62.3% | CN¥931.24 Million | CN¥1.50 Billion | CN¥564.47 Million | ▼ -1.7 pp |
| 2017 | 64.0% | CN¥971.17 Million | CN¥1.52 Billion | CN¥547.42 Million | ▼ -2.7 pp |
| 2016 | 66.7% | CN¥954.85 Million | CN¥1.43 Billion | CN¥477.74 Million | ▼ 0.0 pp |
| 2015 | 66.7% | CN¥872.50 Million | CN¥1.31 Billion | CN¥435.93 Million | ▼ -3.0 pp |
| 2014 | 69.7% | CN¥823.16 Million | CN¥1.18 Billion | CN¥358.17 Million | ▼ -0.7 pp |
| 2013 | 70.4% | CN¥767.16 Million | CN¥1.09 Billion | CN¥323.21 Million | ▼ -8.4 pp |
| 2012 | 78.7% | CN¥651.17 Million | CN¥827.16 Million | CN¥175.99 Million | ▼ -4.0 pp |
| 2011 | 82.7% | CN¥581.17 Million | CN¥702.56 Million | CN¥121.39 Million | ▲ +29.5 pp |
| 2010 | 53.3% | CN¥149.59 Million | CN¥280.84 Million | CN¥131.25 Million | ▲ +7.9 pp |
| 2009 | 45.3% | CN¥117.60 Million | CN¥259.51 Million | CN¥141.91 Million | ▼ -2.3 pp |
| 2008 | 47.6% | CN¥106.70 Million | CN¥224.15 Million | CN¥117.45 Million | — |